These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 12435166)

  • 21. Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: weighing the evidence.
    Cohen SB; Cohen MD; Cush JJ; Fleischmann RM; Mease PJ; Schiff MH; Simon LS; Weaver AL
    J Rheumatol Suppl; 2008 Feb; 81():4-30; quiz 31-4. PubMed ID: 19193621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice.
    Sfriso P; Salaffi F; Montecucco CM; Bombardieri S; Todesco S
    Reumatismo; 2009; 61(2):132-9. PubMed ID: 19633800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment and management of early RA: A primary care primer.
    Costenbader KH; Kountz DS
    J Fam Pract; 2007 Jul; 56(7 Suppl):S1-7; quiz S8. PubMed ID: 17605944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rheumatoid arthritis treatment and monitoring of outcomes--where are we [corrected] in 2007?
    Yazici Y; Abramson SB
    Bull NYU Hosp Jt Dis; 2007; 65(4):300-5. PubMed ID: 18081549
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden.
    Kristensen LE; Saxne T; Geborek P
    Arthritis Rheum; 2006 Feb; 54(2):600-6. PubMed ID: 16447237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Biologics in rheumatology. Targeted therapy--and what must be considered].
    Fischer A
    MMW Fortschr Med; 2010 Sep; 152(38):12. PubMed ID: 20960670
    [No Abstract]   [Full Text] [Related]  

  • 27. Integrating biologic therapy into the comprehensive care of patients with rheumatoid arthritis.
    Lipsky PE
    J Rheumatol Suppl; 2005 Jan; 72():54-7. PubMed ID: 15660470
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are there special considerations relevant to trials of biologic agents?
    Strand V
    J Rheumatol Suppl; 1994 Sep; 41():41-5; discussion 45-9. PubMed ID: 7799384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are biologics more effective than classical disease-modifying antirheumatic drugs?
    Nurmohamed MT; Dijkmans BA
    Arthritis Res Ther; 2008; 10(5):118. PubMed ID: 18828888
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differences in longitudinal disease and treatment characteristics of patients with rheumatoid arthritis replying and not replying to a postal questionnaire. Experience from a biologics register in southern Sweden.
    Söderlin MK; Jacobsson LT; Petersson IF; Englund M; Saxne T; Geborek P
    J Rheumatol; 2009 Jun; 36(6):1166-9. PubMed ID: 19411397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How to predict prognosis in early rheumatoid arthritis.
    Morel J; Combe B
    Best Pract Res Clin Rheumatol; 2005 Feb; 19(1):137-46. PubMed ID: 15588975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response.
    American College of Rheumatology Committee to Reevaluate Improvement Criteria
    Arthritis Rheum; 2007 Mar; 57(2):193-202. PubMed ID: 17330293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The future use of biologic therapies in combination for the treatment of rheumatoid arthritis.
    Strand V
    J Rheumatol Suppl; 1996 Mar; 44():91-6. PubMed ID: 8833063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early rheumatoid arthritis.
    Scott DL
    Br Med Bull; 2007; 81-82():97-114. PubMed ID: 17540693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. B cell-directed therapy in rheumatoid arthritis--clinical experience.
    Panayi GS
    J Rheumatol Suppl; 2005 Feb; 73():19-24; discussion 29-30. PubMed ID: 15693112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biologic therapy for early rheumatoid arthritis: the latest evidence.
    Castro-Rueda H; Kavanaugh A
    Curr Opin Rheumatol; 2008 May; 20(3):314-9. PubMed ID: 18388524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update on biologics in juvenile idiopathic arthritis.
    Ilowite NT
    Curr Opin Rheumatol; 2008 Sep; 20(5):613-8. PubMed ID: 18698187
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessing the safety of biologic therapies in rheumatoid arthritis: the challenges of study design.
    Hyrich KL
    J Rheumatol Suppl; 2005 Jan; 72():48-50. PubMed ID: 15660468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The BeSt story: on strategy trials in rheumatoid arthritis.
    Klarenbeek NB; Allaart CF; Kerstens PJ; Huizinga TW; Dijkmans BA
    Curr Opin Rheumatol; 2009 May; 21(3):291-8. PubMed ID: 19318946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early rheumatoid arthritis -- is there a window of opportunity?
    Cush JJ
    J Rheumatol Suppl; 2007 Nov; 80():1-7. PubMed ID: 17985417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.